122 related articles for article (PubMed ID: 9829837)
1. Pharmacokinetics and biodistribution of radioimmunoconjugates of anti-CD19 antibody and single-chain Fv for treatment of human B-cell malignancy.
Li Q; Hudson W; Wang D; Berven E; Uckun FM; Kersey JH
Cancer Immunol Immunother; 1998 Nov; 47(3):121-30. PubMed ID: 9829837
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
3. Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA.
Wang D; Li Q; Hudson W; Berven E; Uckun F; Kersey JH
Bioconjug Chem; 1997; 8(6):878-84. PubMed ID: 9404661
[TBL] [Abstract][Full Text] [Related]
4. Optimization of conditions for formation and analysis of anti-CD19 FVS191 single-chain Fv homodimer (scFv')2.
Wang D; Berven E; Li Q; Uckun F; Kersey JH
Bioconjug Chem; 1997; 8(1):64-70. PubMed ID: 9026037
[TBL] [Abstract][Full Text] [Related]
5. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma.
Goel A; Baranowska-Kortylewicz J; Hinrichs SH; Wisecarver J; Pavlinkova G; Augustine S; Colcher D; Booth BJ; Batra SK
J Nucl Med; 2001 Oct; 42(10):1519-27. PubMed ID: 11585867
[TBL] [Abstract][Full Text] [Related]
6. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments.
Ferl GZ; Kenanova V; Wu AM; DiStefano JJ
Mol Cancer Ther; 2006 Jun; 5(6):1550-8. PubMed ID: 16818514
[TBL] [Abstract][Full Text] [Related]
7. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
Uckun FM; Chelstrom LM; Irvin JD; Finnegan D; Gunther R; Young J; Kuebelbeck V; Myers DE; Houston LL
Blood; 1992 May; 79(10):2649-61. PubMed ID: 1375109
[TBL] [Abstract][Full Text] [Related]
8. Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.
Meany HJ; Seibel NL; Krailo M; Villaluna D; Chen Z; Gaynon P; Neglia JP; Park JR; Hutchinson R; Sato JK; Wells RJ; Woods WG; Reaman G
J Immunother; 2015 Sep; 38(7):299-305. PubMed ID: 26261894
[TBL] [Abstract][Full Text] [Related]
9. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
Kenanova V; Olafsen T; Williams LE; Ruel NH; Longmate J; Yazaki PJ; Shively JE; Colcher D; Raubitschek AA; Wu AM
Cancer Res; 2007 Jan; 67(2):718-26. PubMed ID: 17234783
[TBL] [Abstract][Full Text] [Related]
10. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates.
Messinger Y; Yanishevski Y; Ek O; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Clin Cancer Res; 1998 Jan; 4(1):165-70. PubMed ID: 9516966
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.
Vallera DA; Elson M; Brechbiel MW; Dusenbery KE; Burns LJ; Jaszcz WB; Ramsay NK; Panoskaltsis-Mortar A; Kuroki DW; Wagner JE; Vitetta ES; Kersey JH
Cancer Biother Radiopharm; 2004 Feb; 19(1):11-23. PubMed ID: 15068607
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I
Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of three recombinant single chain antibody fragments (scFvs) directed against the CD19 antigen.
Bejcek BE; Wang D; Berven E; Pennell CA; Peiper SC; Poppema S; Uckun FM; Kersey JH
Cancer Res; 1995 Jun; 55(11):2346-51. PubMed ID: 7538901
[TBL] [Abstract][Full Text] [Related]
14. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
Uckun FM; Manivel C; Arthur D; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Gunther R
Blood; 1992 May; 79(9):2201-14. PubMed ID: 1373967
[TBL] [Abstract][Full Text] [Related]
15. In vivo toxicity and pharmacokinetic features of B43(Anti-CD19)-Genistein immunoconjugate.
Ek O; Yanishevski Y; Zeren T; Waurzyniak B; Gunther R; Chelstrom L; Chandan-Langlie M; Schneider E; Myers DE; Evans W; Uckun FM
Leuk Lymphoma; 1998 Jul; 30(3-4):389-94. PubMed ID: 9713969
[TBL] [Abstract][Full Text] [Related]
16. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
Uckun FM; Myers DE; Irvin JD; Kuebelbeck VM; Finnegan D; Chelstrom LM; Houston LL
Leuk Lymphoma; 1993 Apr; 9(6):459-76. PubMed ID: 7687916
[TBL] [Abstract][Full Text] [Related]
17. Toxicity profile of the investigational new biotherapeutic agent, B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
Gunther R; Chelstrom LM; Wendorf HR; Schneider EA; Covalciuc K; Johnson B; Clementson D; Irvin JD; Myers DE; Uckun FM
Leuk Lymphoma; 1996 Jun; 22(1-2):61-70, follow.186, color plate II-V. PubMed ID: 8724529
[TBL] [Abstract][Full Text] [Related]
18. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Jansen B; Kersey JH; Jaszcz WB; Gunther R; Nguyen DP; Chelstrom LM; Tuel-Ahlgren L; Uckun FM
Leukemia; 1993 Feb; 7(2):290-7. PubMed ID: 7678881
[TBL] [Abstract][Full Text] [Related]
19. Targeting primary human Ph(+) B-cell precursor leukemia-engrafted SCID mice using radiolabeled anti-CD19 monoclonal antibodies.
Mitchell P; Lee FT; Hall C; Rigopoulos A; Smyth FE; Hekman AM; van Schijndel GM; Powles R; Brechbiel MW; Scott AM
J Nucl Med; 2003 Jul; 44(7):1105-12. PubMed ID: 12843229
[TBL] [Abstract][Full Text] [Related]
20. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
Uckun FM; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Manivel C; Irvin JD; Myers DE; Gunther R
Blood; 1992 Jun; 79(12):3116-29. PubMed ID: 1375841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
